Sökning: WFRF:(Moin A.) > Multicentre prospec...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04084naa a2200769 4500 | |
001 | oai:gup.ub.gu.se/99939 | |
003 | SwePub | |
008 | 240528s2009 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/999392 URI |
024 | 7 | a https://doi.org/10.1007/s00467-008-0931-x2 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Webb, Nicholas J A4 aut |
245 | 1 0 | a Multicentre prospective randomised trial of tacrolimus, azathioprine and prednisolone with or without basiliximab: two-year follow-up data. |
264 | c 2009-01-01 | |
264 | 1 | b Springer Science and Business Media LLC,c 2009 |
520 | a A total of 192 children and adolescents undergoing renal transplantation were randomly chosen to receive tacrolimus, azathioprine and corticosteroids (TAS, n = 93) or tacrolimus, azathioprine, corticosteroids and two doses of basiliximab (TAS + B, n = 99). Six-month outcome data have previously been reported; this manuscript reports the 2-year data. Complete 2-year data were available on 164 (85.4%) of the original 192 patients. There was a single death in the TAS arm. Kaplan-Meier estimates of survival free of graft loss at 2 years were 94.9% in the TAS + B arm and 89.6% in the TAS arm [hazard ratio (HR) 0.52; 95% confidence interval (CI) 0.17 to 1.54, P = 0.23]. Estimates of survival free from rejection at 2 years were 75.2% in the TAS + B arm and 68.7% in the TAS arm (HR 0.81; 95% CI 0.46 to 1.40, P = 0.44). The mean estimated glomerular filtration rate (GFR) at 2 years, was 65.8 ml/min per 1.73 m(2) body surface area in the TAS arm and 66.7 ml/min per 1.73 m(2) in the TAS + B arm (P = 0.78). Blood pressure and cholesterol levels were similar in the two arms, and there was no evidence of a difference in the incidence of infection or malignancy. These data provide further evidence of a lack of benefit associated with the addition of basiliximab to a TAS regimen for European paediatric renal transplant recipients at low immunological risk. | |
653 | a Adolescent | |
653 | a Antibodies | |
653 | a Monoclonal | |
653 | a therapeutic use | |
653 | a Azathioprine | |
653 | a therapeutic use | |
653 | a Child | |
653 | a Drug Therapy | |
653 | a Combination | |
653 | a Female | |
653 | a Glomerular Filtration Rate | |
653 | a Graft Rejection | |
653 | a immunology | |
653 | a prevention & control | |
653 | a Humans | |
653 | a Immunosuppression | |
653 | a Immunosuppressive Agents | |
653 | a therapeutic use | |
653 | a Kidney Transplantation | |
653 | a immunology | |
653 | a Male | |
653 | a Prednisolone | |
653 | a therapeutic use | |
653 | a Prospective Studies | |
653 | a Recombinant Fusion Proteins | |
653 | a therapeutic use | |
653 | a Tacrolimus | |
653 | a therapeutic use | |
700 | 1 | a Prokurat, Sylwester4 aut |
700 | 1 | a Vondrak, Karel4 aut |
700 | 1 | a Watson, Alan R4 aut |
700 | 1 | a Hughes, David A4 aut |
700 | 1 | a Marks, Stephen D4 aut |
700 | 1 | a Moghal, Nadeem E4 aut |
700 | 1 | a Fitzpatrick, Maggie M4 aut |
700 | 1 | a Milford, David V4 aut |
700 | 1 | a Saleem, Moin A4 aut |
700 | 1 | a Jones, Caroline A4 aut |
700 | 1 | a Friman, Styrbjörn,d 1948u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för kirurgi,Institute of Clinical Sciences, Department of Surgery4 aut0 (Swepub:gu)xfrist |
700 | 1 | a Van Damme-Lombaerts, Rita4 aut |
700 | 1 | a Janssen, Francoise4 aut |
700 | 1 | a Hamer, Clare4 aut |
700 | 1 | a Rhodes, Sarah4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för kliniska vetenskaper, Avdelningen för kirurgi4 org |
773 | 0 | t Pediatric nephrology (Berlin, Germany)d : Springer Science and Business Media LLCg 24:1, s. 177-82q 24:1<177-82x 0931-041Xx 1432-198X |
856 | 4 8 | u https://gup.ub.gu.se/publication/99939 |
856 | 4 8 | u https://doi.org/10.1007/s00467-008-0931-x |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy